Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginsenoside CK in preparation of external drugs to treat atopic dermatitis

A technology for atopic dermatitis and ginsenosides, which is applied in the field of medicine, can solve the problems such as few reports on the research effect of atopic dermatitis, and achieve the effects of low recurrence rate, clear active ingredients and stable drug effect.

Inactive Publication Date: 2019-06-21
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, some scholars at home and abroad have reported that ginsenoside CK has a certain inhibitory effect on various tumor cells including hepatocellular carcinoma, nasopharyngeal carcinoma, colon cancer, and bladder cancer, but the research effect of ginsenoside on atopic dermatitis is scarce. There are reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside CK in preparation of external drugs to treat atopic dermatitis
  • Application of ginsenoside CK in preparation of external drugs to treat atopic dermatitis
  • Application of ginsenoside CK in preparation of external drugs to treat atopic dermatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-5

[0051] Embodiment 1-5 treats atopic dermatitis topical ointment

[0052] Take ginsenoside CK and conventional pharmaceutical carriers according to the weight percentage of the composition in Table 1, prepare according to the conventional preparation method of ointment, and keep it sealed for future use.

Embodiment 6-10

[0053] Example 6-10 Treatment of atopic dermatitis cosmetic health care spray

[0054] Take ginsenoside CK and conventional pharmaceutical carriers according to the weight percentage of the composition in Table 1, prepare according to the conventional preparation method of cosmetic health care spray, and then seal and store for future use.

Embodiment 11

[0055] Embodiment 11 Animal experiments (1)

[0056] In this experiment, a mouse model of atopic dermatitis induced by ovalbumin antigen (OVA) percutaneous sensitization was established and divided into groups, and then ginsenoside CK (low, medium, high concentration) and positive drug (dexamethasone) were used to treat the atopic dermatitis mice. The mice were administered externally, and the therapeutic effects of the mice in each group were observed.

[0057] 1. Experimental materials

[0058] 1. Experimental animals:

[0059] Balb / c mice (female, 6 weeks old, SPF grade, number 60) were kept in the animal room, and the animal room was maintained at a 12:12 hour light-dark cycle, the temperature was 25±2°C, and the humidity 55±15%. Mice were fed with a standard laboratory diet (LabDiet Autoclavable Rodent Diet 5010, PMI International Nutrition, Brentwood, USA), and after two weeks of adaptation, OVA sensitization was performed.

[0060] 2. OVA was purchased from Sigma-Al...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical treatment, in particular to application of ginsenoside CK in the preparation of external drugs and health cosmetics to treat atopic dermatitis.OVA-sensitized (ovalbumin-sensitized) atopic dermatitis mouse models are established; filaggrin gene-deficient atopic dermatitis mice are selected; the two types of mice are fed with ginsenoside CK with different concentrations. The results show that ginsenoside CK can evidently reduce the scratching frequency of the OVA- sensitized AD (atopic dermatitis) model mice and reduce epidermal and dermalthickness of the mice; the therapeutic effect of a medium concentration group and that of the high concentration group are evidently higher than that of the low concentration group and that of a dexamethasone cream group; ginsenoside CK can reduce dermatitis score and scratching frequency of Ft mice and the expression of IL-4 at skin lesions of the Ft mice, the therapeutic effect of the medium concentration group is higher than that of the low concentration group and that of the high concentration group, and dexamethasone cream cannot improve atopic dermatitis type skin lesions with skin barrier dysfunction caused by filaggrin gene deficiency. The external drugs and health cosmetics made with ginsenoside CK herein have the advantages of good therapeutic effect and good safety.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of ginsenoside CK in the preparation of external medicine for treating atopic dermatitis and cosmetic health products. Background technique [0002] Atopic dermatitis (Atopic Dermatitis, AD) is a chronic, relapsing, inflammatory skin disease. Patients often experience severe itching symptoms, which seriously affect the quality of life. The disease usually first occurs in infancy, and the onset before 1 year old accounts for about 50% of all patients. The disease is a chronic process, and some patients can be delayed to adulthood, but there are also adults with onset. In developed countries, the prevalence of this disease in children can be as high as 10% to 20%. In my country, the prevalence rate of atopic dermatitis has been gradually increasing in the past 20 years. In 1998, the total prevalence rate of school-age adolescents (6-20 years old) was 0.70%. ) prev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P17/00A61P29/00A61K8/63A61Q19/00
Inventor 张慧敏王东明马欣杨莉莉李文徐平丁佩军何翔边风华顾志英
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com